Onxeo Announces Publication of Preclinical Study Results Comparing Efficacy and Toxicity of olaparib and AsiDNA™ in Frontiers in Oncology
In-vivo Models Showed that Only AsiDNA™ Could Delay Resistance to Carboplatin without Increasing its Toxicity
Paris (France), November 13, 2019 – 6:00 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) in oncology, in particular against rare or resistant cancers, today announced the publication of the results of preclinical studies comparing the efficacy and toxicity of two DNA repair inhibitors: olaparib, a PARP inhibitor, and AsiDNA™, the Company’s first-in-class DDR inhibitor, in the peer-reviewed journal, Frontiers in Oncology. In-vivo models showed that, while both DNA repair inhibitors were effective, only AsiDNA™ could delay resistance to carboplatin without increasing its toxicity.
Françoise BONO, Chief Scientific Officer of Onxeo, commented: "The results of these in-vivo studies highlighted the distinctive characteristics of our clinical stage product candidate, AsiDNA™. Most importantly, these studies show AsiDNA’s™ ability to delay resistance to carboplatin without increasing its toxicity, a critical property that has not previously been observed in anti-cancer agents, including olaparib. In addition, the studies confirmed the overall good safety profile of AsiDNA™. These translational studies, conducted in collaboration with the research laboratory of Marie Dutreix at the Institut Curie, were instrumental in our decision to prioritize the clinical development of AsiDNA™ in combination with chemotherapy. We now look forward to the preliminary data from our ongoing DRIIV-1b Phase 1b clinical study of AsiDNA™ in combination with a reference chemotherapy (carboplatin and paclitaxel), expected in a few weeks."
The original research article, titled “Preclinical studies comparing efficacy and toxicity of DNA repair inhibitors, olaparib and AsiDNA, in treatment of carboplatin resistant tumors,” is currently available on the Frontiers in Oncology website.